Thursday - May 22, 2025
FDA Approves Johnson & Johnson's IMAAVY(TM) (nipocalimab-aahu) a New Treatment for Myasthenia Gravis (MG), Offering Hope for Families
May 01, 2025
CHICAGO, Illinois, May 1 -- The Muscular Dystrophy Association issued the following news release:

* * *

FDA Approves Johnson & Johnson's IMAAVY(TM) (nipocalimab-aahu) a New Treatment for Myasthenia Gravis (MG), Offering Hope for Families

First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older.

Muscular Dystrophy Association (MDA) applauds the U.S. Food and Dr . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products